About Us

BerGenBio AS is a privately-held biotech company built on proprietary Screening technology used for the research and pre-clinical development of novel drug targets, associated biomarkers and first in class therapeutics for the treatment of cancer, with lead programs against metastatic drug resistant solid tumors, EMT and drug resistance.

With its headquarters in Bergen Norway, BerGenBio has established a fully integrated research and development infrastructure that discovers and validates novel drug targets and rapidly develops therapeutics against these. With a profound understanding of cancer biology and unique target validation data the company is able to lead the world with first in class therapeutic leads and early clinical data.

BerGenBio’s is driven by a powerful technology platform called CellSelect that provides greater biological insight to the role and function of targets and illustrates therapeutic benefit through regulated dose response therapeutically mimetic studies of target inhibition and translational preclinical modeling.

BerGenBio offers contract & partnered research collaborations to the global biopharmaceutical industry providing advanced target discovery, validation, genetic dose response, disease modeling and high through put candidate screening at pre IND stage and early clinical development. Many proprietary cell lines, assays and genome subset screening libraries are available.

Key applications include:

• Identification of novel targets through phenotypic screening
• Validation of novel targets to confirm role for target within the disease model
• Determination of target therapeutic threshold in regulated "in vivo" disease treatment models
• Identification of the true target of promiscuous drugs and which target is playing an active role in the disease model
• Determine optimal degree of relative knockdown when multiple targets are active
• Identification of drug to target hit to identify the targets for drugs leads and natural compounds
• Determination of escape pathways through genetic screening to identify genes that mediate resistance to the therapeutic

Our robust technology combined with our deep understanding of cancer biology, in particular the tumor micro-environment, EMT and mechanisms of drug resistance, makes BerGenBio a premier partner for pharmaceutical and biotechnology companies working in oncology.